Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 18/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.62 |
| ▸ | MMP2 | P08253 | 14/20 | 0.62 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563860 | 1.00 | ADAM10 (0.62) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL3458689 | 1.00 | ADAM10 (0.62) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL2174366 | 0.84 | ADAM10 (0.53) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL6024779 | 0.83 | ADAM10 (0.65) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL2422925 | 0.83 | ADAM10 (0.65) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL2174203 | 0.83 | ADAM10 (0.65) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL2172909 | 0.82 | ADAM10 (0.69) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL2172902 | 0.82 | ADAM10 (0.69) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL2174471 | 0.82 | ADAM10 (0.69) | ADAM10ERBB2MMP2MMP8MMP12 | |
| SCHEMBL3457555 | 0.80 | ADAM10 (0.64) | ADAM10ERBB2MMP2MMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | ADAM10 26/4885ERBB2 3036/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.